Why the study?
What are the risk factors and mechanisms of terfenadine-induced torsade de pointes?
Population
Patients taking terfenadine, healthy volunteers in pharmacokinetic studies, and in vitro models
Design
Review
Authors
Loading...
Supports avoiding terfenadine with CYP3A4 inhibitors or liver dysfunction; leaves open prospective validation of torsade mechanisms.
What are the risk factors and mechanisms of terfenadine-induced torsade de pointes?
Terfenadine should not be used at supratherapeutic doses, with CYP3A4 inhibitors, or in patients with liver dysfunction or predisposing factors for QT prolongation due to the risk of torsade de pointes.
Thomas Y. K. Chan (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: